HomeCompareRXN vs JNJ

RXN vs JNJ: Dividend Comparison 2026

RXN yields 17.82% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RXN wins by $138.33M in total portfolio value
10 years
RXN
RXN
● Live price
17.82%
Share price
$64.95
Annual div
$11.57
5Y div CAGR
50.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$138.36M
Annual income
$116,858,378.81
Full RXN calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — RXN vs JNJ

📍 RXN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRXNJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RXN + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RXN pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RXN
Annual income on $10K today (after 15% tax)
$1,514.30/yr
After 10yr DRIP, annual income (after tax)
$99,329,621.99/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, RXN beats the other by $99,325,584.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RXN + JNJ for your $10,000?

RXN: 50%JNJ: 50%
100% JNJ50/50100% RXN
Portfolio after 10yr
$69.19M
Annual income
$58,431,564.35/yr
Blended yield
84.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

RXN
Analyst Ratings
7
Buy
6
Hold
Consensus: Buy
Price Target
$38.00
-41.5% upside vs current
Range: $38.00 — $38.00
Altman Z
7.0
Piotroski
8/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RXN buys
0
JNJ buys
0
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$RXN▼ Sell$1,001 - $15,0002020-07-22
Gilbert Cisneros🏢 House$RXN▼ Sell$1,001 - $15,0002020-07-21
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRXNJNJ
Forward yield17.82%2.14%
Annual dividend / share$11.57$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR50.6%28%
Portfolio after 10y$138.36M$30.5K
Annual income after 10y$116,858,378.81$4,749.88
Total dividends collected$136.57M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$38.00$228.73

Year-by-year: RXN vs JNJ ($10,000, DRIP)

YearRXN PortfolioRXN Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$13,383$2,682.98$10,594$274.49+$2.8KRXN
2$19,373$5,053.71$11,294$360.69+$8.1KRXN
3$31,027$10,296.91$12,133$476.91+$18.9KRXN
4$56,408$23,209.93$13,156$635.42+$43.3KRXN
5$119,749$59,391.58$14,432$854.61+$105.3KRXN
6$305,588$177,456.86$16,056$1,162.76+$289.5KRXN
7$964,361$637,382.07$18,175$1,604.53+$946.2KRXN
8$3,862,898$2,831,031.49$21,009$2,252.68+$3.84MRXN
9$20,094,278$15,960,977.10$24,911$3,229.73+$20.07MRXN
10$138,359,256$116,858,378.81$30,458$4,749.88+$138.33MRXN

RXN vs JNJ: Complete Analysis 2026

RXNStock

Rexnord Corporation designs, manufactures, and markets process and motion control, and water management products worldwide. It operates in two segments, Process & Motion Control Platform and Water Management Platform. The company offers table top conveying chain and related accessories, metal conveying and engineered woven metals, gearing and gear drives, conveying equipment, industrial chain, and custom assemblies; custom-engineered, application-specific miniature gearboxes, and motion control assemblies and components used in aerospace, defense, medical equipment, robotics, semiconductor, instrumentation, and satellite communications; and shaft management products, including couplings, torque limiters, electromagnetic clutches and brakes, industrial bearings, and shaft locking assemblies. It also provides aerospace components for use in door systems, engine accessories and controls, engine mounts, flight control systems, gearboxes, landing gears, and rotor pitch controls. The company offers valve, distribution and drainage, and site work products; water conservation and finish plumbing products; and commercial electric hand dryers. It sells products through distribution partners, independent sales representatives, plumbing wholesalers, industry-specific distributors, and sales agencies to commercial construction, institutional, infrastructure, and residential construction end market, as well as to original equipment manufacturers and end users. The company offers its products under the Rexnord, Rex, Addax, Euroflex, Falk, FlatTop, Cambridge, Link-Belt, Omega, PSI, Shafer, Stearns, Highfield, Thomas, Centa, Tollok, Zurn, Wilkins, Green Turtle, World Dryer, JUST, Aquaflush, AquaSense, AquaVantage, AquaSpec, EcoVantage, Zurn One, and Zurn One Systems names. Rexnord Corporation was incorporated in 2006 and is headquartered in Milwaukee, Wisconsin.

Full RXN Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this RXN vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RXN vs SCHDRXN vs JEPIRXN vs ORXN vs KORXN vs MAINRXN vs ABBVRXN vs MRKRXN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.